Q-omics provides the consensus-scored RPS6P16 profile across patient tissues and cancer cell-line models. RPS6P16 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, RPS6P16 is differentially expressed in 7, with the highest sampling consensus in THCA. Additionally, RPS6P16 RNA expression shows 9,001 significant protein co-abundance associations, with the highest sampling consensus in CCRCC. Together, these results highlight ACC, THCA, and CCRCC as cancer lineages where RPS6P16 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPS6P16 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPS6P16 survival associations across molecular data types. RPS6P16 RNA expression shows survival associations in the most cancer types (22). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPS6P16 RNA expression–survival associations across cancer types. High RPS6P16 expression shows unfavorable associations in ACC, KIRC, COAD and KICH, but favorable associations in GBM and READ. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for RPS6P16 RNA expression.
This table summarizes RPS6P16 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for RPS6P16. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPS6P16 shows lower tumor expression in THCA, BRCA and LUSC and higher tumor expression in COAD, PRAD and KIRC. The THCA box plot shows higher RPS6P16 RNA expression in normal versus tumor tissue (log2 FC = −0.124, t-test p < 0.001).
This table shows molecular features associated with RPS6P16 in patient tissues and cancer cell lines. In patient samples, RPS6P16 shows the broadest associations at the RNA and protein expression levels, with CCRCC recurring as the lineage with the largest associated feature set.
